In our research, individuals treated with IL-17 inhibitors had a lower IR of either melanoma or NMSC than those on IL-23 inhibitors (0.06 vs. 0.10 per 100 PYs and 0.19 vs. 0.49 per 100 PYs, respectively). The gene discussed is IL17A; the disease is melanoma.